• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful 13-year ongoing remission with C5 inhibitor therapy following renal transplant in atypical hemolytic uremic syndrome.

作者信息

Mostafa Mariam A, Zand Martin, Taylor Jeremy, Kouides Peter

机构信息

Rochester General Hospital, Rochester, New York, USA.

Faculty of Medicine, Ain Shams University, Cairo, Egypt.

出版信息

Am J Hematol. 2024 Nov;99(11):2241-2243. doi: 10.1002/ajh.27461. Epub 2024 Aug 23.

DOI:10.1002/ajh.27461
PMID:39177420
Abstract
摘要

相似文献

1
Successful 13-year ongoing remission with C5 inhibitor therapy following renal transplant in atypical hemolytic uremic syndrome.非典型溶血性尿毒症综合征肾移植后采用C5抑制剂治疗持续缓解13年
Am J Hematol. 2024 Nov;99(11):2241-2243. doi: 10.1002/ajh.27461. Epub 2024 Aug 23.
2
Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation.抗C5作为亲属活体肾移植中不典型溶血尿毒综合征的预防性治疗。
Transplantation. 2013 Aug 27;96(4):e26-9. doi: 10.1097/TP.0b013e31829d388d.
3
Efficacy and Safety of Eculizumab in Kidney Transplant Patients With Primary Atypical Hemolytic-Uremic Syndrome.依库珠单抗治疗原发性非典型溶血尿毒综合征肾移植患者的疗效和安全性。
Transplant Proc. 2022 Jan-Feb;54(1):25-26. doi: 10.1016/j.transproceed.2021.09.063. Epub 2021 Dec 12.
4
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.长效 C5 抑制剂 ravulizumab 对补体抑制剂治疗初治的儿童非典型溶血尿毒症综合征患者有效且安全。
Kidney Int. 2021 Jul;100(1):225-237. doi: 10.1016/j.kint.2020.10.046. Epub 2020 Dec 8.
5
Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.高度个体化的补体阻断治疗在肾移植后临床结局和非典型溶血尿毒综合征的肾脏流行病学中的应用已经发生了革命性变化。
J Am Soc Nephrol. 2019 Dec;30(12):2449-2463. doi: 10.1681/ASN.2019040331. Epub 2019 Oct 1.
6
Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.监测非典型溶血性尿毒症综合征患者依库珠单抗治疗的补体功能检测。
J Thromb Haemost. 2014 Sep;12(9):1440-8. doi: 10.1111/jth.12615. Epub 2014 Jul 16.
7
Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.依库珠单抗在日本成人非典型溶血性尿毒症综合征患者中的安全性和有效性：上市后监测的中期分析
Clin Exp Nephrol. 2019 Jan;23(1):65-75. doi: 10.1007/s10157-018-1609-8. Epub 2018 Jun 29.
8
Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.依库珠单抗抗补体 C5 治疗阵发性睡眠性血红蛋白尿症和非典型溶血尿毒综合征。
Transl Res. 2015 Feb;165(2):306-20. doi: 10.1016/j.trsl.2014.10.010. Epub 2014 Oct 20.
9
Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis.非典型溶血性尿毒症综合征患者的定制依库珠单抗治疗方案：全面补体分析的必要性
J Thromb Haemost. 2014 Sep;12(9):1437-9. doi: 10.1111/jth.12639. Epub 2014 Jul 15.
10
Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis: comment.针对非典型溶血性尿毒症综合征患者的定制依库珠单抗治疗方案：全面补体分析的必要性：评论
J Thromb Haemost. 2015 Mar;13(3):485-6. doi: 10.1111/jth.12764. Epub 2014 Dec 6.

引用本文的文献

1
Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry Analysis.非典型溶血性尿毒症综合征肾移植受者从依库珠单抗转换为ravulizumab的有效性和安全性：一项全球非典型溶血性尿毒症综合征注册研究分析
Clin Transplant. 2025 Sep;39(9):e70278. doi: 10.1111/ctr.70278.
2
Treatment of atypical hemolytic uremic syndrome with eculizumab in a patient presenting with neuropsychiatric prodrome: a case report.用依库珠单抗治疗表现为神经精神前驱症状的非典型溶血尿毒综合征患者：一例报告
Front Immunol. 2025 Apr 8;16:1542973. doi: 10.3389/fimmu.2025.1542973. eCollection 2025.